<DOC>
	<DOCNO>NCT00054886</DOCNO>
	<brief_summary>The primary goal study evaluate effectiveness safety SU-011,248 treatment metastatic kidney cancer .</brief_summary>
	<brief_title>Study Safety Efficacy SU-011,248 Adult Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Eligible patient must least 18 year age diagnosis metastatic kidney cancer . The patient 's kidney cancer must get bad during/after previous cytokinebased therapy give . Any side effect prior therapy must subside , blood urine test must show adequate bone marrow , liver , kidney function Prior treatment systemic therapy 1 prior cytokinebased treatment regimen ; Prior surgical resection irradiation site measurable disease ; Ongoing severe hematuria ; Other active second malignancy ; Cardiovascular diseases condition within last 12 month ; Known brain metastasis ; Known HIVpositive AIDSrelated illness ; Pregnant breastfeed woman ; Current participation clinical trial ; Other severe acute chronic medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
</DOC>